Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Eloxx Pharmaceuticals, Inc. | v450276_ex31-1.htm |
| 10-K - FORM 10-K - Eloxx Pharmaceuticals, Inc. | v450276_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Eloxx Pharmaceuticals, Inc. | v450276_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Eloxx Pharmaceuticals, Inc. | v450276_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Eloxx Pharmaceuticals, Inc. | v450276_ex31-2.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement (Nos. 333-178881, 333-177586, 333-167388, 333-157417, 333-140238,
333-104105, 333-187133 and 333-195688) on Form S-8 and Registration Statement (Nos. 333-170140, 333-166277, 333-148779, 333-146691,
333-138405, and 333-201891) on Form S-3 of Sevion Therapeutics, Inc. and Subsidiaries of our report dated October 13, 2016,
relating to our audits of the consolidated financial statements, included in this Annual Report on Form 10-K of the Sevion Therapeutics,
Inc. and Subsidiaries for the year ended June 30, 2016. Our report dated October 13, 2016, relating to the consolidated financial
statements includes an explanatory paragraph relating to an uncertainty as to the Company's ability to continue as a going concern.
/s/ RSM US LLP
New York, New York
October 13, 2016